Lung Adenocarcinoma Latest Advances

Ubiquitin-dependent degradation of MBD3 by TRIM59 promotes lung adenocarcinoma.

Journal: Acta biochimica et biophysica Sinica

Published: April 15, 2026

Expert Consensus on Shared Decision-making in the Diagnosis and Treatment  of Ground-glass Opacity-featured Lung Adenocarcinoma

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer

Published: April 14, 2026

AKT2 for Modifying the Tumor Immune Microenvironment in Lung Adenocarcinoma.

Journal: Clinical laboratory

Published: April 14, 2026

MiR-200a-5p Is a Potential Prognostic Marker for Lung Adenocarcinoma: Based on Transcriptomics, Bioinformatics, and In Vitro and In Vivo Experiments.

Journal: Folia biologica

Published: April 14, 2026

Impact assessment of [18F]FDG PET/CT in predicting EGFR gene mutation status in patients with lung adenocarcinoma using recovery coefficient-based correction of semi-quantitative and volume-based PET metrics.

Journal: Nuklearmedizin. Nuclear medicine

Published: April 13, 2026

RETRACTION: Guanylate-Binding Protein 1 Correlates With Advanced Tumor Features and Serves as a Prognostic Biomarker for Worse Survival in Lung Adenocarcinoma Patients.

Journal: Journal of clinical laboratory analysis

Published: April 13, 2026

Correction to "Prognostic and Monitoring Utility of Serum CEA in Lung Adenocarcinoma: Differential Roles in EGFR-TKI and Chemotherapy Treatments".

Journal: Cancer medicine

Published: April 10, 2026

Defining mutational signatures of lung cancer-associated carcinogens through in vitro exposure of human airway epithelial cells.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Understanding Adenocarcinoma of the Lung Developing from Subsolid Nodules and Atypical Pulmonary Cysts.

Journal: Radiographics : a review publication of the Radiological Society of North America, Inc

Published: April 09, 2026

Exploring the anti-tumor potential of saxagliptin in A549 lung adenocarcinoma cells.

Journal: Wiadomosci lekarskie (Warsaw, Poland : 1960)

Published: April 09, 2026

Genetic mutation and dysfunction of AT2 cells drive B(a)P/LPS-induced inflammation-related lung tumorigenesis: evidence and mechanism of autophagy.

Journal: Acta biochimica et biophysica Sinica

Published: April 09, 2026

Efficacy of Vebreltinib in Advanced Lung Adenocarcinoma With c-MET Amplification.

Journal: American journal of therapeutics

Published: April 09, 2026

Lung Adenocarcinoma Latest Advances

Find the Latest Research About Lung Adenocarcinoma

Ubiquitin-dependent degradation of MBD3 by TRIM59 promotes lung adenocarcinoma.

Ubiquitin-dependent degradation of MBD3 by TRIM59 promotes lung adenocarcinoma.

Expert Consensus on Shared Decision-making in the Diagnosis and Treatment of Ground-glass Opacity-featured Lung Adenocarcinoma

Expert Consensus on Shared Decision-making in the Diagnosis and Treatment of Ground-glass Opacity-featured Lung Adenocarcinoma

AKT2 for Modifying the Tumor Immune Microenvironment in Lung Adenocarcinoma.

AKT2 for Modifying the Tumor Immune Microenvironment in Lung Adenocarcinoma.

MiR-200a-5p Is a Potential Prognostic Marker for Lung Adenocarcinoma: Based on Transcriptomics, Bioinformatics, and In Vitro and In Vivo Experiments.

MiR-200a-5p Is a Potential Prognostic Marker for Lung Adenocarcinoma: Based on Transcriptomics, Bioinformatics, and In Vitro and In Vivo Experiments.

Impact assessment of [18F]FDG PET/CT in predicting EGFR gene mutation status in patients with lung adenocarcinoma using recovery coefficient-based correction of semi-quantitative and volume-based PET metrics.

Impact assessment of [18F]FDG PET/CT in predicting EGFR gene mutation status in patients with lung adenocarcinoma using recovery coefficient-based correction of semi-quantitative and volume-based PET metrics.

RETRACTION: Guanylate-Binding Protein 1 Correlates With Advanced Tumor Features and Serves as a Prognostic Biomarker for Worse Survival in Lung Adenocarcinoma Patients.

RETRACTION: Guanylate-Binding Protein 1 Correlates With Advanced Tumor Features and Serves as a Prognostic Biomarker for Worse Survival in Lung Adenocarcinoma Patients.

Correction to "Prognostic and Monitoring Utility of Serum CEA in Lung Adenocarcinoma: Differential Roles in EGFR-TKI and Chemotherapy Treatments".

Correction to "Prognostic and Monitoring Utility of Serum CEA in Lung Adenocarcinoma: Differential Roles in EGFR-TKI and Chemotherapy Treatments".

Defining mutational signatures of lung cancer-associated carcinogens through in vitro exposure of human airway epithelial cells.

Defining mutational signatures of lung cancer-associated carcinogens through in vitro exposure of human airway epithelial cells.

Understanding Adenocarcinoma of the Lung Developing from Subsolid Nodules and Atypical Pulmonary Cysts.

Understanding Adenocarcinoma of the Lung Developing from Subsolid Nodules and Atypical Pulmonary Cysts.

Exploring the anti-tumor potential of saxagliptin in A549 lung adenocarcinoma cells.

Exploring the anti-tumor potential of saxagliptin in A549 lung adenocarcinoma cells.

Genetic mutation and dysfunction of AT2 cells drive B(a)P/LPS-induced inflammation-related lung tumorigenesis: evidence and mechanism of autophagy.

Genetic mutation and dysfunction of AT2 cells drive B(a)P/LPS-induced inflammation-related lung tumorigenesis: evidence and mechanism of autophagy.

Efficacy of Vebreltinib in Advanced Lung Adenocarcinoma With c-MET Amplification.

Efficacy of Vebreltinib in Advanced Lung Adenocarcinoma With c-MET Amplification.

Expert Consensus on Shared Decision-making in the Diagnosis and Treatment  of Ground-glass Opacity-featured Lung Adenocarcinoma

Expert Consensus on Shared Decision-making in the Diagnosis and Treatment  of Ground-glass Opacity-featured Lung Adenocarcinoma